MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its position as the leader in the field with another set of stellar data, this time in metastatic squamous non-small cell lung cancer on a first-line basis.
Ook interessant voor je
Reageer